Women who take multivitamin supplements before their breast cancer diagnosis and during chemotherapy appear to be less likely to develop the debilitating, often long-lasting symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.
Mark L. Fuerst
Children covered by Medicaid when diagnosed with cancer have similar survival rates compared with children with private insurance, according to a new study. Evidence shows a slightly increased risk of cancer death among uninsured children, which may be related to a more advanced stage at diagnosis.
Annual mammography screening starting at age 40 prevents the most breast cancer deaths, according to a comparison of the three most common screening recommendations.
Significant racial and gender-based disparities exist in outcomes among patients with squamous cell carcinoma of the anus, with black men having the lowest survival rates, according to a new study.
More privately insured cancer patients seeking to participate in clinical trials received approval since the passage of the Affordable Care Act, according to a new study.
Niraparib is the most effective but most costly of the currently FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
An intraoperative, multimodal optical cancer detection system can detect brain cancer with high degrees of accuracy, sensitivity, and specificity in real time during surgery, according to a new study.
A personalized peptide vaccination shows clinical benefit for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.
Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.
An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.